Literature review and economic evaluation of oral and intramuscular ziprasidone treatment among patients with schizophrenia in China

• 作者: Congpei Zhang Dongdong Liu Fen Du Lili Yang Wei Hao Xin Gao Xin Yu Yu-Chen Yeh
• 来源期刊: 综合精神医学(英文)
• 学科: 医学
• 关键词: cost ZIPRASIDONE LITERATURE The ECT
• 年，卷（期）: zhjsyxyw_2018,（6）
• 页码范围: 115-121
• 页数: 7页
• 分类号: R

摘要

Background Over 10 million Chinese are affected by schizophrenia.The annual cost of schizophrenia in China was estimated at US$2586per patient. Aims The study has two aims:(1)to conduct a targeted literature review of the economic literature on oral ziprasidone in China,and (2)to develop an inpatient economic model that compared the cost of intramuscular ziprasidone with other regimens including electroconvulsive therapy (ECT)for the management of acute agitation in patients with schizophrenia from a hospital's perspective in China. Methods A targeted literature review was conducted using PubMed and the Chinese literature databases for studies published between January 2007 and December 2017.Studies that assessed costs associated with oral ziprasidone treatment for schizophrenia in China were summarised.In the inpatient economic model, cost measures included hospital room and board, antipsychotics,ECT and medications for the management of extrapyramidal symptoms (EPS).Input for standard antipsychotic regimens and unit cost were obtained from the literature.Hospital length of stay (LOS),utilisation of ECT and incidence of EPS were derived from the literature and supplemented/validated with a survey of psychiatrists in China.Cost was presented in 2017 Chinese yuan. Results The average estimated LOS was 29 days with ziprasidone,33 days with risperidone+benzodiazepine, 32 days with olanzapine,35 days with haloperidol and 29 days with ECT.The cost of antipsychotics was ￥1260 with ziprasidone,￥137 with risperidone+benzodiazepine,￥913 with olanzapine and ￥210 with haloperidol;ECT treatment costs ￥785.The base-case analysis suggested that higher antipsychotic cost with ziprasidone was offset by savings with shorter LOS.Using intramuscular ziprasidone for acute management was associated with a total cost of ￥11 157,the lowest among all antipsychotic regimens ￥11424 with risperidone+benzodiazepine,￥11711with olanzapine and ￥11912 with haloperidol)and slightly higher than ECT (￥10606).The cost of antipsy